$443,702,768
to FRED HUTCHINSON CANCER CENTER
HVTN LABORATORY PROGRAM
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Ongoing support for the HIV Vaccine Trials Network laboratory program, a 20-year research initiative studying vaccine candidates and immune responses.
HVTN is a cornerstone of U.S. HIV vaccine development; this 2006-launched effort remains critical to pandemic preparedness and infectious-disease countermeasures.
Sustains demand for specialized laboratory equipment, reagents, and bioanalytical services supporting vaccine immunogenicity testing and clinical trial infrastructure.
HIV vaccine development is a strategic biotech priority; sustained U.S. investment maintains leadership in vaccine science against global competitors.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-17. Cost: $0.002967.
- 2026-06-05LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIALS NETWORK$1.1B
- 2026-05-21LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS; HIV VACCINE TRIALS NETWORK$383.5M
- 2026-05-21CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)$221.9M
- 2026-04-20EARLY DETECTION RESEARCH NETWORK: DATA MANAGEMENT AND COORDINATING CENTER$67.7M
- 2026-04-27IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)$38.3M
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier ASST_NON_UM1AI068618_075.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.